A prespecified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF DM trials demonstrated that significantly more patients treated with Wegovy 2.4 mg SC once weekly had an improvement of at least one in New York Heart Association (NYHA) functional class compared to those who received placebo (32.6% versus 21.5%, respectively
Spirulina in Clinical Practice: Evidence-Based Human Applications - PMC 5
Coenzyme Q 10 supplementation was well tolerated at all doses and resulted in a slower deterioration of function in Parkinson's disease patients in the group taking 1,200 mg/day
Nicola Magrini, Unit head for Innovation, Evidence synthesis and Clinical research, University Hospital, Bologna, Italy, Co-Chair of the Guidelines Development Group Comments: GLP-1 and inclusion in the essential medicine Mr Deus Mubangizi, Director, Medicines and Health Products Policies and Standards Department, WHO Panel discussion Ms Jeanette Hunter General Primary Health Care at the National Department of Health (NDoH) of South Africa, and Co-Chair of the Guidelines Development Group
